Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-09-11

Clinical Trial Update: PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PS-341 (bortezomib) alone and with EPOCH chemotherapy for Non-Hodgkin lymphoma; results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Velcade (bortezomib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: B-Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2012-09-11